5,766 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Pincus Capital Management LP

Pincus Capital Management LP purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, HoldingsChannel reports. The firm purchased 5,766 shares of the medical research company’s stock, valued at approximately $3,341,000. Thermo Fisher Scientific makes up 2.2% of Pincus Capital Management LP’s investment portfolio, making the stock its 11th largest position.

Other institutional investors have also added to or reduced their stakes in the company. High Note Wealth LLC raised its stake in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the period. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Beacon Financial Strategies CORP purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Core Wealth Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $30,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research note on Thursday, May 14th. Barclays lowered their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $616.10.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. This represents a 3.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $493.18 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $183.27 billion, a price-to-earnings ratio of 27.11, a PEG ratio of 2.18 and a beta of 0.88. The stock has a 50 day moving average of $480.40 and a 200 day moving average of $533.68. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.